Miki Murata

Miki Murata

Auto-generated profile, based on publicly available information

Miki Murata

Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center, Moriguchi, Osaka, Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2023 in JMIR Formative Research
Verified
Journal Article
Open access
NYNoriyo YAMASHIKI
Noriyo YAMASHIKI
KKKyoko Kawabata
Kyoko Kawabata
MMMiki Murata
Miki Murata
SIShunichiro Ikeda
Shunichiro Ikeda
TFTakako Fujimaki
Takako Fujimaki
MNMakoto Naganuma
Makoto Naganuma
Background: Screening and intervention for alcohol use disorders (AUDs) are recommended to improve the prognosis of patients with alcohol-related liver disease (ALD). Most patients’ smartphone app diaries record drinking behavior for self-monitoring. A smartphone app can be expected to also be helpful for physicians because it can provide rich patient information to hepatologists, leading to suitable feedback. We conducted this prospective pilot study to assess the use of a smartphone app as a journaling tool and as a self-report–based feedback source for patients with ALD. Objective: The aims of this study were assessment of whether journaling (self-report) and self-report–based feedback can help patients maintain abstinence and improve liver function data. Methods: This pilot study used a newly developed smartphone journaling app for patients, with input data that physicians can review. After patients with ALD were screened for harmful alcohol use, some were invited to use the smartphone journaling app for 8 weeks. Their self-reported alcohol intake, symptoms, and laboratory data were recorded at entry, week 4, and week 8. Biomarkers for alcohol use included gamma glutamyl transferase (GGT), percentage of carbohydrate-deficient transferrin to transferrin (%CDT), and GGT-CDT (GGT-CDT= 0.8 × ln[GGT] + 1.3 × ln[%CDT]). At each visit, their recorded data were reviewed by a hepatologist to evaluate changes in alcohol consumption and laboratory data. The relation between those outcomes and app usage was also investigated. Results: Of 14 patients agreeing to participate, 10 completed an 8-week follow-up, with diary input rates between 44% and 100% of the expected days. Of the 14 patients, 2 withdrew from clinical follow-up, and 2 additional patients never used the smartphone journaling app. Using the physician’s view, a treating hepatologist gave feedback via comments to patients at each visit. Mean self-reported alcohol consumption dropped from baseline (100, SD 70 g) to week 4 (13, SD 25 g; P=.002) and remained lower at week 8 (13, SD 23 g; P=.007). During the study, 5 patients reported complete abstinence. No significant changes were found in mean GGT and mean %CDT alone, but the mean GGT-CDT combination dropped significantly from entry (5.2, SD 1.2) to the week 4 visit (4.8, SD 1.1; P=.02) and at week 8 (4.8, SD 1.0; P=.01). During the study period, decreases in mean total bilirubin (3.0, SD 2.4 mg/dL to 2.4, SD 1.9 mg/dL; P=.01) and increases in mean serum albumin (3.0, SD 0.9 g/dL to 3.3, SD 0.8 g/dL; P=.009) were recorded. Conclusions: These pilot study findings revealed that a short-term intervention with a smartphone journaling app used by both patients and treatment-administering hepatologists was associated with reduced drinking and improved liver function. Trial Registration: UMIN CTR UMIN000045285; http://tinyurl.com/yvvk38tj

5 March 2026 in JMIR Formative Research
Verified
Journal Article
Open access
NYNoriyo YAMASHIKI
Noriyo YAMASHIKI
NKNoriko Kudo
Noriko Kudo
KKKyoko Kawabata
Kyoko Kawabata
TFTakako Fujimaki
Takako Fujimaki
EAEiji Aramaki
Eiji Aramaki
MNMakoto Naganuma
Makoto Naganuma
Background: Alcohol-related liver disease (ALD) is a global health concern, and harmful alcohol use negatively affects clinical outcomes and health-related quality of life (HRQOL). Previous studies have demonstrated impaired HRQOL in chronic liver disease, including ALD; however, evidence remains limited regarding whether hepatologist-delivered abstinence support in outpatient practice can improve HRQOL. Digital interventions such as smartphone journaling apps may support behavior change, but their effectiveness in hepatology-led care settings has not been well established. Objective: This study aimed to prospectively evaluate changes in HRQOL over time among patients with ALD receiving routine hepatologist-led abstinence support supplemented by a smartphone-based journaling app. Methods: This was a prospective single-arm observational study. Eligibility criteria included a diagnosis of ALD, outpatient follow-up in hepatology, advice to abstain from alcohol, and written informed consent; patients were excluded if they reported abstinence for >1 year, had no intention to reduce or abstain from alcohol, or declined medical follow-up. In total, 21 outpatients with ALD (mean age 51, SD 3 years; men: n=12, 57.1%) were enrolled from a gastroenterology and hepatology outpatient clinic between August 2021 and July 2023 (convenience sampling). Participants attended scheduled visits at 4, 8, 12, and 24 weeks and received brief abstinence counseling by hepatologists while using a journaling app. HRQOL was assessed using the Japanese version of the 36-Item Short Form Health Survey version 2 at entry, week 8, and week 24. Changes in subscale and summary scores were analyzed using paired t tests (2-sided α=.05) with 95% CIs; when normality assumptions were not met, Wilcoxon signed-rank tests were applied. Results: From entry to week 8, significant improvements were observed in physical functioning (mean difference [MD] +4.70, 95% CI 1.62-7.78; P=.005), role physical (MD +7.87, 95% CI 1.05-14.70; P=.02), general health (MD +5.82, 95% CI 1.74-9.88; P=.007), and role emotional (MD +7.85, 95% CI 0.29-15.41; P=.04). The Physical Component Summary score also improved (MD +4.78, 95% CI 1.22-8.34; P=.01). These findings were consistent in sensitivity analysis using the Wilcoxon signed-rank test. No significant changes were observed in mental or social HRQOL domains. In subgroup analyses, patients who maintained abstinence during the first 8 weeks (7/21, 33.3%) showed continued improvement in physical HRQOL up to 24 weeks, whereas those who continued drinking (11/21, 52.4%) did not exhibit meaningful change. Conclusions: In this exploratory observational study, hepatologist-led abstinence support supplemented by a smartphone-based journaling app was associated with improvements in physical HRQOL. Unlike previous studies that have focused on addiction specialist–led interventions, this study evaluated abstinence support delivered by hepatologists in routine outpatient practice, providing a real-world assessment of a digitally supported approach. These findings suggest that hepatologist-led, digitally supported care may be a feasible strategy in clinical settings with limited access to specialized addiction services.

23 July 2025 in JMIR Preprints
Verified
Preprint
Open access
NYNoriyo YAMASHIKI
Noriyo YAMASHIKI
NKNoriko Kudo
Noriko Kudo
KKKyoko Kawabata
Kyoko Kawabata
TFTakako Fujimaki
Takako Fujimaki
EAEiji Aramaki
Eiji Aramaki
MNMakoto Naganuma
Makoto Naganuma
BACKGROUND Alcohol-related liver disease (ALD) is a global health concern, and harmful alcohol use negatively affects clinical outcomes and health-related quality of life (HRQOL). Previous studies have demonstrated impaired HRQOL in chronic liver disease, including ALD; however, evidence remains limited regarding whether hepatologist-delivered abstinence support in outpatient practice can improve HRQOL. Digital interventions such as smartphone journaling apps may support behavior change, but their effectiveness in hepatology-led care settings has not been well established. OBJECTIVE This study aimed to prospectively evaluate changes in HRQOL over time among patients with ALD receiving routine hepatologist-led abstinence support supplemented by a smartphone-based journaling app. METHODS This was a prospective single-arm observational study. Eligibility criteria included a diagnosis of ALD, outpatient follow-up in hepatology, advice to abstain from alcohol, and written informed consent; patients were excluded if they reported abstinence for >1 year, had no intention to reduce or abstain from alcohol, or declined medical follow-up. In total, 21 outpatients with ALD (mean age 51, SD 3 years; men: n=12, 57.1%) were enrolled from a gastroenterology and hepatology outpatient clinic between August 2021 and July 2023 (convenience sampling). Participants attended scheduled visits at 4, 8, 12, and 24 weeks and received brief abstinence counseling by hepatologists while using a journaling app. HRQOL was assessed using the Japanese version of the 36-Item Short Form Health Survey version 2 at entry, week 8, and week 24. Changes in subscale and summary scores were analyzed using paired t tests (2-sided α=.05) with 95% CIs; when normality assumptions were not met, Wilcoxon signed-rank tests were applied. RESULTS From entry to week 8, significant improvements were observed in physical functioning (mean difference [MD] +4.70, 95% CI 1.62-7.78; P=.005), role physical (MD +7.87, 95% CI 1.05-14.70; P=.02), general health (MD +5.82, 95% CI 1.74-9.88; P=.007), and role emotional (MD +7.85, 95% CI 0.29-15.41; P=.04). The Physical Component Summary score also improved (MD +4.78, 95% CI 1.22-8.34; P=.01). These findings were consistent in sensitivity analysis using the Wilcoxon signed-rank test. No significant changes were observed in mental or social HRQOL domains. In subgroup analyses, patients who maintained abstinence during the first 8 weeks (7/21, 33.3%) showed continued improvement in physical HRQOL up to 24 weeks, whereas those who continued drinking (11/21, 52.4%) did not exhibit meaningful change. CONCLUSIONS In this exploratory observational study, hepatologist-led abstinence support supplemented by a smartphone-based journaling app was associated with improvements in physical HRQOL. Unlike previous studies that have focused on addiction specialist–led interventions, this study evaluated abstinence support delivered by hepatologists in routine outpatient practice, providing a real-world assessment of a digitally supported approach. These findings suggest that hepatologist-led, digitally supported care may be a feasible strategy in clinical settings with limited access to specialized addiction services. CLINICALTRIAL

4 December 2022 in JMIR Preprints
Verified
Preprint
Open access
NYNoriyo YAMASHIKI
Noriyo YAMASHIKI
KKKyoko Kawabata
Kyoko Kawabata
MMMiki Murata
Miki Murata
SIShunichiro Ikeda
Shunichiro Ikeda
TFTakako Fujimaki
Takako Fujimaki
MNMakoto Naganuma
Makoto Naganuma
BACKGROUND Screening and intervention for alcohol use disorders (AUDs) are recommended to improve the prognosis of patients with alcohol-related liver disease (ALD). Most patients’ smartphone app diaries record drinking behavior for self-monitoring. A smartphone app can be expected to also be helpful for physicians because it can provide rich patient information to hepatologists, leading to suitable feedback. We conducted this prospective pilot study to assess the use of a smartphone app as a journaling tool and as a self-report–based feedback source for patients with ALD. OBJECTIVE The aims of this study were assessment of whether journaling (self-report) and self-report–based feedback can help patients maintain abstinence and improve liver function data. METHODS This pilot study used a newly developed smartphone journaling app for patients, with input data that physicians can review. After patients with ALD were screened for harmful alcohol use, some were invited to use the smartphone journaling app for 8 weeks. Their self-reported alcohol intake, symptoms, and laboratory data were recorded at entry, week 4, and week 8. Biomarkers for alcohol use included gamma glutamyl transferase (GGT), percentage of carbohydrate-deficient transferrin to transferrin (%CDT), and GGT-CDT (GGT-CDT= 0.8 × ln[GGT] + 1.3 × ln[%CDT]). At each visit, their recorded data were reviewed by a hepatologist to evaluate changes in alcohol consumption and laboratory data. The relation between those outcomes and app usage was also investigated. RESULTS Of 14 patients agreeing to participate, 10 completed an 8-week follow-up, with diary input rates between 44% and 100% of the expected days. Of the 14 patients, 2 withdrew from clinical follow-up, and 2 additional patients never used the smartphone journaling app. Using the physician’s view, a treating hepatologist gave feedback via comments to patients at each visit. Mean self-reported alcohol consumption dropped from baseline (100, SD 70 g) to week 4 (13, SD 25 g; P=.002) and remained lower at week 8 (13, SD 23 g; P=.007). During the study, 5 patients reported complete abstinence. No significant changes were found in mean GGT and mean %CDT alone, but the mean GGT-CDT combination dropped significantly from entry (5.2, SD 1.2) to the week 4 visit (4.8, SD 1.1; P=.02) and at week 8 (4.8, SD 1.0; P=.01). During the study period, decreases in mean total bilirubin (3.0, SD 2.4 mg/dL to 2.4, SD 1.9 mg/dL; P=.01) and increases in mean serum albumin (3.0, SD 0.9 g/dL to 3.3, SD 0.8 g/dL; P=.009) were recorded. CONCLUSIONS These pilot study findings revealed that a short-term intervention with a smartphone journaling app used by both patients and treatment-administering hepatologists was associated with reduced drinking and improved liver function. CLINICALTRIAL UMIN CTR UMIN000045285; http://tinyurl.com/yvvk38tj